Patient-Derived Xenograft Model Market Expected to Reach $1.12 Billion by 2031

Overview of the Patient-Derived Xenograft Model Market



The patient-derived xenograft (PDX) model market is rapidly expanding, projected to reach approximately $1.12 billion by 2031. This remarkable growth is primarily driven by the escalating prevalence of cancer and a rising demand for diagnostic tools aimed at rare diseases. According to a report by The Insight Partners, the market size was $468.75 million in 2024, anticipating a CAGR of 13.4% during the forecast period.

What Are Patient-Derived Xenograft Models?



PDX models are integral to cancer research, allowing for human tumor tissues or cells to be implanted into immunodeficient or humanized mice. This process simulates human tumor biology, offering insights into natural cancer progression. Researchers widely adopt these models for drug development, preclinical trials, and personalized cancer therapies.

Key Findings


As reported by the International Agency for Research on Cancer, cancer cases are projected to exceed 35 million by 2050, up from 20 million in 2022. Lung cancer remains the most commonly diagnosed cancer worldwide, constituting 12.4% of all newly reported instances, followed by breast and colorectal cancers. The pharmaceutical industry is responding to this surge by investing heavily in the development of PDX models to improve the success rates of clinical trials and facilitate the introduction of innovative therapies.

These models are especially crucial for creating targeted treatments and immunotherapies, necessitating precise preclinical validation. For instance, Charles River's NCG model efficiently hosts xenograft cells, human immune system components, and tumor tissue, allowing in-depth studies into tumor biology and immuno-oncology.

Technological Innovations


Recent advancements in technologies such as CRISPR gene editing, next-generation sequencing, and improved imaging techniques have significantly boosted the complexity and precision of PDX models. These enhancements enable researchers to replicate human tumor biology more accurately, thereby increasing the validity of preclinical studies. A 2023 study in PubMed Central established two new PDX models for acute leukemias, utilizing a combination of ultra-sensitive proteomics and CRISPR-Cas9 reverse genetics to explore potential therapeutic targets within the bone marrow microenvironment.

Geographic Trends


In terms of market share, North America led the field in 2024, followed closely by Europe and the Asia-Pacific region, which is predicted to have the highest growth rate during the forecast period. The patient-derived xenograft model market is categorized by factors such as type — with the mice model dominating — and application, with preclinical drug development holding the largest market share.

Competitive Landscape


Prominent players in the patient-derived xenograft model market include:
  • - Champions Oncology, Inc.
  • - Charles River Laboratories, Inc.
  • - Crown Bioscience, Inc.
  • - EPO Berlin-Buch GmbH
  • - Hera BioLabs
  • - Horizon Discovery Group plc
  • - Oncodesign
  • - Pharmatest Services Ltd.
  • - Urolead
  • - Xentech

Conclusion


The increasing incidence of cancer alongside ongoing technological developments in PDX models is driving market growth significantly. These models preserve the histological and genetic features of original tumors, providing critical insights into cancer progression, new therapies, and accurate clinical outcome predictions. Furthermore, the integration of CRISPR-Cas9 technology into PDX models is enhancing both their precision and effectiveness, presenting an invaluable tool for researchers and healthcare institutions alike.
Moreover, stakeholders, including model developers, academic organizations, and healthcare facilities, find critical insights in The Insight Partners report to navigate this evolving landscape and unlock new growth opportunities.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.